Press Releases

Oxcarbazepine Oral Suspension, USP 300 mg/5 mL is available in 250 mL bottles.

Point-of-care testing services enhance patient care, support pharmacy revenue

This annual award, overseen by NASPA and sponsored by Upsher-Smith, acknowledges innovative pharmacists from across the nation for their outstanding contributions to the field of pharmacy.

Camber Pharmaceuticals is pleased to announce the addition of Paliperidone Extended-Release Tablets to its current portfolio.

The National Community Pharmacists Association is pleased to announce that it has named Mark Ey, RPh, as its new chief operating officer.

Quality Products, Innovative Technology, and Exceptional Customer Service Characterize a Successful Inaugural Year

The podcast aims to explore and discuss various pharmacy-related topics with insights from industry experts, highlighting the transformative role of technology in today's evolving pharmacy landscape.

Dr. Reddy’s acquired the entire MenoLabs supplements portfolio which includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause.

Company also secures 'Gold Medal' status from global sustainability ratings agency, EcoVadis

Under the Agreement, Dr. Reddy’s will obtain commercialization rights for COYA 302 in the United States, Canada, the European Union and the United Kingdom, for patients with ALS.

Camber Pharmaceuticals is pleased to announce the addition of Famotidine Powder for Oral Suspension, USP to its current portfolio.

Advocacy and professional groups join global diabetes care company at Nasdaq to bring awareness to diabetes and commemorate 100 years of serving people with diabetes

Camber Pharmaceuticals is pleased to announce the addition of Eplerenone Tablets to its current portfolio.

Walden will oversee enterprise marketing teams, customer experience, and digital as well as lead the expansion of Thrifty Ice Cream.

- Adds first ready-to-use presentation of key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma. - Represents a high value, complex product launch for Amneal’s expanding injectable portfolio.

Aurigene is investing $40m Mn USD in an R&D and pilot scale facility as a first step towards a series of strategic investments